{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:22:11Z","timestamp":1782829331690,"version":"3.54.5"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Systemic lupus erythematosus (SLE) is a classic immune complex-mediated autoimmune disease that arises from the loss of tolerance to specific self-antigens (such as nuclear antigens). It can cause severe organ damage, leading to lifelong disabilities and potentially life-threatening manifestations. While some new therapeutic options for SLE have been approved in recent years, many patients remain refractory to treatment, making it difficult to achieve remission or low disease activity. While the focus of novel therapies in the pipeline mainly lies on (cell-depleting) biological or cell-based therapies, the better understanding of the disease pathogenesis has revealed several intracellular targets, the inhibition of which could nicely contribute to a more effective treatment strategy in SLE. We provide a concise summary of key receptor signaling pathways \u2013 including immuno-, Toll-like and type I interferon receptors \u2013 involved in the pathogenesis of SLE. We put special emphasis on intracellular molecules with their current or potential role as therapeutic targets in the control of this devastating disorder. Overall, our aim was to draw attention to the field of signal transduction therapy in SLE, which already has a partial role in the current treatment guidelines, but could have more beneficial contributions to the future therapy of this autoimmune disorder.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1735301","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:52:28Z","timestamp":1767768748000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Signaling pathways in systemic lupus erythematosus and therapeutic implications"],"prefix":"10.3389","volume":"16","author":[{"given":"Lili","family":"Balogh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor Gyula","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0211-0","article-title":"B cell checkpoints in autoimmune rheumatic diseases","volume":"15","author":"Rubin","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"110222","DOI":"10.1016\/j.clim.2024.110222","article-title":"The abnormal signaling of the B cell receptor and co-receptors of lupus B cells","volume":"263","author":"Liossis","year":"2024","journal-title":"Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.60","article-title":"T cells as therapeutic targets in SLE","volume":"6","author":"Crispin","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2007.12.003","article-title":"How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype","volume":"29","author":"Crispin","year":"2008","journal-title":"Trends Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13577","article-title":"Exhausted T cells in systemic lupus erythematosus patients in long-standing remission","volume":"204","author":"Lima","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2015.91","article-title":"Toll-like receptors: potential targets for lupus treatment","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00826-z","article-title":"Emerging concepts of type I interferons in SLE pathogenesis and therapy","volume":"18","author":"Psarras","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nri3477","article-title":"The role of dendritic cells in autoimmunity","volume":"13","author":"Ganguly","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12341","article-title":"Fc\u03b3 receptors: genetic variation, function, and disease","volume":"268","author":"Hargreaves","year":"2015","journal-title":"Immunol Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000527213","article-title":"Aberrant B-cell activation in systemic lupus erythematosus","volume":"8","author":"Kang","year":"2022","journal-title":"Kidney Dis (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213391","article-title":"Aberrant B cell signaling in autoimmune diseases","volume":"11","author":"Corneth","year":"2022","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.5086a","article-title":"Orelabrutinib, an irreversible inhibitor of Bruton\u2019s tyrosine kinase (Btk), for the treatment of systemic lupus erythematosus (SLE): results of a randomized, double-blind, placebo-controlled, phase Ib\/IIa dose-finding study","volume":"81","author":"Li","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.10.008","article-title":"BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"108640","DOI":"10.1016\/j.clim.2020.108640","article-title":"BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis","volume":"223","author":"Chalmers","year":"2021","journal-title":"Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"26164","DOI":"10.1038\/srep26164","article-title":"Therapeutic blockade of immune complex-mediated glomerulonephritis by highly selective inhibition of Bruton\u2019s tyrosine kinase","volume":"6","author":"Chalmers","year":"2016","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1115244","article-title":"Dual inhibition of phosphoinositide 3-kinases \u03b4 and \u03b3 reduces chronic B cell activation and autoantibody production in a mouse model of lupus","volume":"14","author":"Olayinka-Adefemi","year":"2023","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41584-022-00815-2","article-title":"Ikaros, Aiolos and other moving targets to treat SLE","volume":"18","author":"Boulougoura","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"8383","DOI":"10.3390\/ijms21218383","article-title":"Trans-ancestral fine-mapping and epigenetic annotation as tools to delineate functionally relevant risk alleles at IKZF1 and IKZF3 in systemic lupus erythematosus","volume":"21","author":"Vyse","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"New Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01088","article-title":"Aberrant T cell signaling and subsets in systemic lupus erythematosus","volume":"9","author":"Katsuyama","year":"2018","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2017.11.008","article-title":"TCR signaling: mechanisms of initiation and propagation","volume":"43","author":"Courtney","year":"2018","journal-title":"Trends Biochem Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.7416","article-title":"Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus","volume":"177","author":"Jury","year":"2006","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042858","article-title":"Voclosporin: A comprehensive review of its role as a novel calcineurin inhibitor in the management of systemic lupus erythematosus","volume":"104","author":"Ashinze","year":"2025","journal-title":"Medicine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.003097","article-title":"GRK2 mediates TCR-induced transactivation of CXCR4 and TCR-CXCR4 complex formation that drives PI3K\u03b3\/PREX1 signaling and T cell cytokine secretion","volume":"293","author":"Dinkel","year":"2018","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"112557","DOI":"10.1016\/j.intimp.2024.112557","article-title":"Inhibition of GRK2 ameliorates the pristane-induced mouse SLE model by suppressing plasma cells differentiation","volume":"138","author":"Han","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/ijms26051851","article-title":"A comprehensive review of Fc\u03b3 receptors and their role in systemic lupus erythematosus","volume":"26","author":"Sep\u00falveda-Delgado","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1124\/mol.113.089821","article-title":"Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy","volume":"85","author":"Lamphier","year":"2014","journal-title":"vivo Mol Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.09.015","article-title":"IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans","volume":"29","author":"Isnardi","year":"2008","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/biomedicines12010138","article-title":"Targeting TLR signaling cascades in systemic lupus erythematosus and rheumatoid arthritis: an update","volume":"12","author":"Kalliolias","year":"2024","journal-title":"Biomedicines"},{"key":"B40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3899\/jrheum.2025-0390.O010","article-title":"Randomized, placebo-controlled phase II study of enpatoran, a small molecule Toll-like receptor 7\/8 inhibitor, in cutaneous lupus erythematosus results from cohort A","volume":"52","author":"Pearson","year":"2025","journal-title":"J Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004701","article-title":"Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I\/II study in systemic lupus erythematosus","volume":"10","author":"Tanaka","year":"2024","journal-title":"RMD Open"},{"key":"B42","doi-asserted-by":"publisher","first-page":"106648","DOI":"10.1016\/j.intimp.2020.106648","article-title":"TJ-M2010-5, a novel MyD88 inhibitor, corrects R848-induced lupus-like immune disorders of B cells in vitro","volume":"85","author":"Zou","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600583","article-title":"Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity","volume":"198","author":"Dudhgaonkar","year":"2017","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.606489","article-title":"The role of structure in the biology of interferon signaling","volume":"11","author":"Walter","year":"2020","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/art.42926","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: A phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03299-0","article-title":"Design of two randomized, placebo-controlled, phase 3 trials of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in systemic lupus erythematosus","volume":"42","author":"Arriens","year":"2025","journal-title":"Adv Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.675542","article-title":"Tofacitinib ameliorates lupus through suppression of T cell activation mediated by TGF-\u03b2 type I receptor","volume":"12","author":"Yan","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-07103-2","article-title":"Tofacitinib therapy in systemic lupus erythematosus with arthritis: a retrospective study","volume":"43","author":"Yan","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae163.021","article-title":"Clinical outcomes and predictors of difficult-to-treat lupus nephritis: observations from a single center retrospective cohort","volume":"63","author":"Jagan","year":"2024","journal-title":"Rheumatology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01210-9","article-title":"Opportunities and limitations of B cell depletion approaches in SLE","volume":"21","author":"Stockfelt","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2092470","article-title":"Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis","volume":"15","author":"van Gelder","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e005742","DOI":"10.1136\/rmdopen-2025-005742","article-title":"Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study","volume":"11","author":"Merrill","year":"2025","journal-title":"RMD Open"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1735301\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:52:29Z","timestamp":1767768749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1735301\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2025.1735301"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1735301","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1735301"}}